Key elements of bioanalytical method validation for macromolecules
Journal Title: The AAPS Journal - Year 2007, Vol 9, Issue 2
Abstract
The Third American Association of Pharmaceutical Scientists/US Food and Drug Administration (FDA) Bioanalytical Workshop, which was held May 1 and 2, 2006, in Arlington, VA, addressed bioanalytical assays that are being used for the quantification of therapeutic candidates in support of pharmacokinetic evaluations. One of the main goals of this workshop was to discuss best practices used in bioanalysis regardless of the size of the therapeutic candidates. Since the last bioanalytical workshop, technological advancements in the field and in the statistical understanding of the validation issues have generated a variety of interpretations to clarify and understand the practicality of using the current FDA guidance for assaying macromolecular therapeutics. This article addresses some of the key elements that are essential to the validation of macromolecular therapeutics using ligand binding assays. Because of the nature of ligand binding assays, attempts have been made within the scientific community to use statistical approaches to interpret the acceptance criteria that are aligned with the prestudy validation and in-study validation (sample analysis) processes. We discuss, among other topics, using the total error criterion or confidence interval approaches for acceptance of assays and using anchor calibrators to fit the nonlinear regression models.
Authors and Affiliations
Marian Kelley, Binodh DeSilva
Keywords
Related Articles
- EP ID EP681585
- DOI 10.1208/aapsj0902017
- Views 104
- Downloads 0
Analytical Similarity Assessment in Biosimilar Studies
For assessment of biosimilarity, the US Food and Drug Administration (FDA) recommends a stepwise approach for obtaining the totality-of-the-evidence for demonstrating biosimilarity between a proposed biosimilar product a...
Multidimensional Atomic Force Microscopy: A Versatile Novel Technology for Nanopharmacology Research
The online version of this article (doi:10.1208/s12248-010-9232-y) contains supplementary material, which is available to authorized users.
Emerging Technologies to Increase Ligand Binding Assay Sensitivity
Ligand binding assays (LBAs) have been the method of choice for protein analyte measurements for more than four decades. Over the years, LBA methods have improved in sensitivity and achieved larger dynamic ranges by usin...
The venus flytrap of periplasmic binding proteins: An ancient protein module present in multiple drug receptors
Located between the inner and outer membranes of Gram-negative bacteria, periplasmic binding proteins (PBPs) scavenge or sense diverse nutrients in the environment by coupling to transporters or chemotaxis receptors in t...
Novel Endogenous Glycan Therapy for Retinal Diseases: Safety, In Vitro Stability, Ocular Pharmacokinetic Modeling, and Biodistribution
The online version of this article (doi:10.1208/s12248-014-9563-1) contains supplementary material, which is available to authorized users.